The investigational targeted drug zanubrutinib (BGB-3111) appeared to be highly active, inducing an overall response rate of 83.5 percent in patients with relapsed/refractory mantle cell lymphoma, who were treated in a single-arm, open-label, multicenter, phase 2 trial.
When bad things happen to friends we care about, we often stand in silence because we don't know what to say.
Cancer reminds this survivor that we are much more than our bodies.
The Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients aged 2 or older.
The Food and Drug Administration approved Asparlas (calaspargase pegol-mknl) as a component of a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia (ALL), according to the agency.
I was first diagnosed with cancer when I was six years old, and I can still remember passing the time during treatment by listening to the “weekly top 40” that my brother and I recorded on a cassette tape.
It's not the actual hand we are dealt when live throws us a curve. It's how we play it.
This is the first approval of a PARP inhibitor as a first-line maintenance treatment for BRCA-mutant gynecologic cancers.
The Food and Drug Administration (FDA) granted accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to the agency.
The Food and Drug Administration (FDA) approved BRACAnalysis CDx to be used to identify patients with advanced ovarian cancer who have germline BRCA mutations and are eligible for first line treatment with Lynparza (olaparib) after responding to platinum-based chemotherapy.
The combination use of Imbruvica (ibrutinib) with Rituxan (rituximab) significantly improved survival outcomes compared with standard of care in younger patients with chronic lymphocytic leukemia (CLL).
When a diagnosis begins to improve, it is hard to reconcile your identity as a patient with your identity as a whole. Grappling with questions of who you are after having been diagnosed with something life altering can be both profound and challenging, and leave you a bit, well, ambivalent.
Patients with myeloma who took higher doses of Kyprolis plus dexamethasone tended to have better survival outcomes, according to a recent study.
Single agent Copiktra (duvelisib) induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with Arzerra (ofatumumab).
Two wrongs don't make a right.
Immunotherapy has become a buzzword in the cancer community, but to Sean Parker it’s much more. The 39-year-old billionaire is intensely focused on the promise of immunotherapy, and has become a major force in helping to drive its potential to cure cancers.
To address the lack of information on this younger subset of patients, an international team of researchers analyzed a large dataset from 29 hospital centers in 12 countries.
Rest is an important part of the healing process for those affected by cancer.
A person’s relationship with food can change after a cancer diagnosis, stirring up feelings of anxiety. A recent seminar discussed strategies that can help.
As patients, we need to remember that we may not wear the white coat, but we definitely wear the pants in the doctor-patient relationship
The FDA has approved Herzuma (trastuzumab-pkrb) (Herzuma) as a biosimilar to Herceptin (trastuzumab, Genentech). Trastuzumab-pkrb is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer.
The Food and Drug Administration has approved Nplate for pediatric patients 1 year of age and older with immune thrombocytopenia who have had an insufficient response to medications, such as corticosteroids,or surgery to remove the spleen.
Instead of fighting the roadblocks that cancer can prevent, what would happen if we embraced them?
Cancer has led me to men and women who grabbed onto life but died anyway.
Frontline use of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) significantly reduced the risk for disease progression or death among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), especially in those with high-risk disease.
I try so hard to be positive, but in the back of my mind, I am constantly waiting for the other shoe to drop, for my blood counts to worsen, for the results of the next bone marrow biopsy to be haywire, for the chemo with its side effects to be administered, intensified or changed.
Winter Storm Diego delivered two things... three days off from work and a set of clean scans!
The combination of Darzalex (daratumumab), Revlimid (lenalidomide) and dexamethasone significantly reduced the risk for disease progression in patients with newly diagnosed multiple myeloma.
There are methods to cope with ongoing cancer research and worry.
Here’s another throwback to one of our 2008 issues, where genetic testing was just gaining steam in the cancer space.
